Fisher Funds launched Barramundi on 26 October 2006, 100,000,000 shares issued at $1.00 Par.
Nearly five years later they're 76 cents. What further illustration of the "mighty" Carmel Fisher and her investment team's performance is required....
Printable View
Fisher Funds launched Barramundi on 26 October 2006, 100,000,000 shares issued at $1.00 Par.
Nearly five years later they're 76 cents. What further illustration of the "mighty" Carmel Fisher and her investment team's performance is required....
According to the FF website, Carmel Fisher is the investment manager for the NZ portfolios and a couple of chaps by the names of Frank Jasper and Terry Tollich do all the Australian stock picks. So I'm not sure if Carmel has had too much say in how the Aussie portfolios are run. You would hope Frank and Terry will be on tight leashes now or be replaced.
Roger - Looks like FF has now exited PXS completely. This, from the FF website...
Obviously the drop the in the Pharmaxis share price yesterday was a tremendous disappointment to us and a massive surprise to many investors in the company.
In short it seems that the European Medicines Authority (the regulator) is unlikely, at least at the first hurdle, to grant marketing authorisation for Pharmaxis to market its drug Bronchitol for Cystic Fibrosis in Europe. As the share price response indicates this was a massive negative surprise not only to us but to the analyst and investor community at large.
Assuming that Bronchitol receives a formal negative decision when the regulator meets again in late June (not definite), we believe Pharmaxis will probably appeal the outcome.
This appeal process would represent a delay of 6 months on the original timetable for a European marketing approval, assuming a successful outcome.
The chances of success in the appeal process are difficult to ascertain. Since January 2009 8 drugs have appealed negative decisions, with 3 of those appeals proving successful. PXS believes it will eventually prevail and receive European marketing approval.
The challenge for us right now is to assess what this means for the company’s future. Clearly the risk of ultimate failure to achieve this marketing authorisation has gone up although the key issues raised would seem to be addressable in any review process. Unfortunately, for now though, the risk faced by PXS has risen substantially we have decided to exit our position in the company and watch the review process from the sidelines.
Whilst the balance of probabilities suggests the company may be successful a major negative shock of this scale leads us to believe this is the prudent approach.
These don't look too bad.
Current Unit Price (as at 25 May 2011) $2.1972
Fund Inception June 2005
How has the fund performed as at 30 April 2011
One Month Twelve Months Two Years* Three Years* Since Launch*
Australian Growth
(Average Annual Compound Return) - 0.7% + 18.7% + 32.4% + 12.6% + 9.4%
Benchmark
(90 Day Bank Bill Rate) + 0.2% + 3.1% + 3.0% + 4.4% + 6.2%
Selling Pharmaxis is probably yet another classic example of buying high and selling low.
Sex sells, that picture of her sitting there is designed to seduce aging into "investing" their money, I'll really look after you, YEAH RIGHT. Just another cunning marketing trap.
Yeah I hope those two idiots "managing" if you can call it that, the Australian portfolio are given the boot, there's no excuse for taking such extreme risks with investors money. Get rid of them.
ASX200 in October 2006 5154
ASX200 today 4653